×

Javascript message

This site uses javascript. If javascript is disabled in your browser, some functionality may be impaired.

July 2021
plant_operator

Kromasil facility to be expanded to meet global pharma and biotech demand

Nouryon, a global specialty chemicals leader, plans to invest in its Kromasil manufacturing facility in Bohus, Sweden, to meet the increasing global demand from the pharmaceutical and biotechnology industries for high-performing solutions. The investment is expected to double the facility’s existing production capacity, which will strengthen Nouryon’s global leadership position in high-performance silica.

“This investment reflects Nouryon’s commitment to be a trusted partner to the pharma and biotech industries, which increasingly rely on us to provide solutions that contribute to the production of safe pharmaceuticals,” said Johan Landfors, Executive Vice President and President, Technology Solutions and Europe at Nouryon.

Kromasil products are used by the pharmaceutical, food and beverage, clinical, and environmental industries for applications ranging from laboratory analysis to industrial-scale purification. Kromasil contributes to improved treatment of diabetes as a vital part of the purification of insulin. Other uses include complex bio-pharma applications.

woman taking insuline shot in belly

“Bio-pharmaceuticals, such as peptides, proteins and hormones, are a growing market and we see an increase in demand worldwide, particularly from our customers in India, China and Southeast Asia,” said Patrick Wilhelm, Vice President of Inorganic Specialties at Nouryon. “This facility expansion will reinforce our leadership position in the global high-performance silica market targeted to the pharma and biotech industries, and it will allow us to meet the growing demand for our Kromasil products.”

Construction of the Nouryon facility expansion is scheduled to begin in 2022.

Nouryon is a leading producer of high-performance silica worldwide and has more than 30 years of expertise in spherical silica for analytical to process-scale liquid chromatography under the brand Kromasil. Kromasil chromatography resins offer superior separation performance leading to increased efficiency and decreased costs.

This investment follows Kromasil’s recently introduced efficient purification strategy for GLP-1 agonists used for type 2 diabetes.

Media release on the Nouryon website

June 2021
couple_hiking

Kromasil introduces a purification toolbox for GLP-1 agonists

With the number of people around the world diagnosed with diabetes increasing, the need for adequate treatments are also on the rise. Many of the substances used in production of this type of pharmaceuticals are peptides and have been found challenging to purify, in an efficient way, to the level needed to be approved for safe use by patients. This is where Kromasil's high performing chromatography media now supports the pharmaceutical industry.

“With our efficient purification strategy, it is possible to reach the 99.5 % purity needed for regulatory approval in only two steps compared to three or four steps, which is often the case in the industry today. This translates into greatly improved efficiency and productivity for our customers, said Patrick Wilhelm,” Vice President of Inorganic Specialties at Nouryon.

The new purification toolbox for GLP-1 (glucagon-like peptide-1) agonists such as liraglutide, enables tailor made solutions to the different conditions in our customers production processes and includes procedures that greatly improve the Kromasil media lifetime by increasing the number of purification cycles that can be carried out. This enables our customers to significantly reduce the time needed to optimize their purification process and as a result, a more efficient process.

“Type 2 diabetes patients rely on their medicine every day and, in many cases, it’s a lifelong treatment. We are proud to be able to provide our pharmaceutical customers with solutions that contribute to the promotion of well-being to ensure healthy lives,” said Wilhelm.

To learn more, download our brochure, listen to how our scientists talk about it or get in touch with us:

Get the presentation folder How our people talk about it (Youtube movie) Contact us